公开(公告)号：US20060115485A1

公开(公告)日：2006-06-01

申请号：US11263230

申请日：2005-10-31

申请人： Genevieve Losonsky ,  Edward Connor ,  James Young ,  Herren Wu ,  William Dall'Acqua

发明人： Genevieve Losonsky ,  Edward Connor ,  James Young ,  Herren Wu ,  William Dall'Acqua

IPC分类号： A61K39/42

CPC分类号： C07K16/1027 ,  A61K2039/505 ,  A61K2039/543 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/72 ,  C07K2317/92 ,  C07K2317/94

摘要： The present invention provides methods for preventing, managing, treating and/or ameliorating a Respiratory Syncytial Virus (RSV) infection (e.g., acute RSV disease, or a RSV upper respiratory tract infection (URI) and/or lower respiratory tract infection (LRI)), otitis media (preferably, stemming from, caused by or associated with a RSV infection, such as a RSV URI and/or LRI), and/or a symptom or respiratory condition relating thereto (e.g., asthma, wheezing, and/or reactive airway disease (RAD)) in a subject, comprising administering to said human an effective amount of one or more antibodies that immunospecifically bind to one or more RSV antigens with a high affinity and/or high avidity. In some embodiments, one or more antibodies comprise a modified IgG constant domain, or FcRn-binding fragment thereof resulting in longer in vivo serum half-life. In particular embodiments the methods of the invention comprising administering to subject an effective amount of one or more modified antibodies that immunospecifically bind to one or more RSV antigens with an association rate (kon) of at least 2×105 M−1s−1 and a dissociation rate (koff) of less than 5×10−4 s−1.

摘要翻译： 本发明提供了用于预防，治疗和/或改善呼吸道合胞病毒（RSV）感染（例如急性RSV疾病或RSV上呼吸道感染（URI））和/或下呼吸道感染（LRI）的方法， ），中耳炎（优选来源于，由RSV感染引起或与RSV感染相关联，例如RSV URI和/或LRI），和/或与其相关的症状或呼吸病症（例如，哮喘，喘鸣和/或 反应性气道疾病（RAD）），包括向所述人施用有效量的一种或多种以高亲和力和/或高亲合力免疫特异性结合一种或多种RSV抗原的抗体。 在一些实施方案中，一种或多种抗体包含修饰的IgG恒定结构域或其FcRn结合片段，导致更长的体内血清半衰期。 在具体实施方案中，本发明的方法包括施用有效量的一种或多种经免疫特异性结合一种或多种RSV抗原的修饰的抗体，其具有至少2×10 6的结合速率（kNI） 小于5×10-6的解离速率（k >） 4 -1 。

公开(公告)号：US20110158985A1

公开(公告)日：2011-06-30

申请号：US12969514

申请日：2010-12-15

申请人： GENEVIEVE LOSONSKY ,  EDWARD M. CONNOR ,  JAMES F. YOUNG ,  HERREN WU ,  WILLIAM DALL'ACQUA

发明人： GENEVIEVE LOSONSKY ,  EDWARD M. CONNOR ,  JAMES F. YOUNG ,  HERREN WU ,  WILLIAM DALL'ACQUA

IPC分类号： A61K39/42 ,  A61P31/14

CPC分类号： C07K16/1027 ,  A61K2039/505 ,  A61K2039/543 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/72 ,  C07K2317/92 ,  C07K2317/94

摘要： The present invention provides methods for preventing, managing, treating and/or ameliorating a Respiratory Syncytial Virus (RSV) infection (e.g., acute RSV disease, or a RSV upper respiratory tract infection (URI) and/or lower respiratory tract infection (LRI)), otitis media (preferably, stemming from, caused by or associated with a RSV infection, such as a RSV URI and/or LRI), and/or a symptom or respiratory condition relating thereto (e.g., asthma, wheezing, and/or reactive airway disease (RAD)) in a subject, comprising administering to said human an effective amount of one or more antibodies that immunospecifically bind to one or more RSV antigens with a high affinity and/or high avidity. In some embodiments, one or more antibodies comprise a modified IgG constant domain, or FcRn-binding fragment thereof resulting in longer in vivo serum half-life. In particular embodiments the methods of the invention comprising administering to subject an effective amount of one or more modified antibodies that immunospecifically bind to one or more RSV antigens with an association rate (kon) of at least 2×105 M−1 s−1 and a dissociation rate (koff) of less than 5×10−4 s−1.

摘要翻译： 本发明提供了用于预防，治疗和/或改善呼吸道合胞病毒（RSV）感染（例如急性RSV疾病或RSV上呼吸道感染（URI））和/或下呼吸道感染（LRI）的方法， ），中耳炎（优选来源于，由RSV感染引起或与RSV感染相关联，例如RSV URI和/或LRI），和/或与其相关的症状或呼吸病症（例如，哮喘，喘息和/或 反应性气道疾病（RAD）），包括向所述人施用有效量的一种或多种以高亲和力和/或高亲合力免疫特异性结合一种或多种RSV抗原的抗体。 在一些实施方案中，一种或多种抗体包含修饰的IgG恒定结构域或其FcRn结合片段，导致更长的体内血清半衰期。 在具体实施方案中，本发明的方法包括施用有效量的一种或多种经免疫特异性结合一种或多种具有至少2×105M-1s-1的缔合率（kon）的RSV抗原的修饰的抗体，以及 解离速率（koff）小于5×10-4 s-1。

公开(公告)号：US20110008329A1

公开(公告)日：2011-01-13

申请号：US12600292

申请日：2008-06-25

申请人： Subramaniam Krishnan ,  JoAnn Suzich ,  Peter Kiener ,  Genevieve Losonsky ,  Herren Wu ,  William Dall'Acqua ,  Bettina Richter

发明人： Subramaniam Krishnan ,  JoAnn Suzich ,  Peter Kiener ,  Genevieve Losonsky ,  Herren Wu ,  William Dall'Acqua ,  Bettina Richter

IPC分类号： A61K39/395 ,  C07K16/10 ,  A61P31/14 ,  A61P37/04

CPC分类号： C07K16/1027 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/72 ,  C07K2317/732 ,  C07K2317/77

摘要： The present invention provides methods for managing, treating and/or ameliorating a respiratory syncytial virus (RSV) infection (e.g., acute RSV disease, or a RSV upper respiratory tract infection (URI) and/or lower respiratory tract infection (LRI)), and/or a symptom or a long-term respiratory condition relating thereto (e.g., asthma, wheezing, reactive airway disease (RAD), or chronic obstructive pulmonary disease (COPD)) in a subject, comprising administering to said human an effective amount of one or more antibodies that immunospecifically bind to one or more RSV antigens with a high affinity and/or high avidity and further comprise a modified IgG constant domain, or FcRn-binding fragment thereof, to not only decrease RSV infection, but also decrease the pro-inflammatory epithelial cell immune responses in order to mitigate the later development of asthma and/or wheezing and/or COPD in said patient.

摘要翻译： 本发明提供了用于管理，治疗和/或改善呼吸道合胞病毒（RSV）感染（例如急性RSV疾病或RSV上呼吸道感染（URI）和/或下呼吸道感染（LRI））的方法， 和/或与受试者相关的症状或长期呼吸道状况（例如，哮喘，喘鸣，反应性气道疾病（RAD）或慢性阻塞性肺疾病（COPD））），包括向所述人施用有效量的 一种或多种以高亲和性和/或高亲合力免疫特异性结合一种或多种RSV抗原的抗体，并且还包含经修饰的IgG恒定结构域或其FcRn结合片段，以不仅降低RSV感染，而且减少pro - 炎症性上皮细胞免疫应答，以减轻所述患者中哮喘和/或喘息和/或COPD的后期发展。

公开(公告)号：US20100098708A1

公开(公告)日：2010-04-22

申请号：US12559375

申请日：2009-09-14

申请人： Genevieve Losonsky ,  Edward M. Connor ,  James F. Young ,  Herren Wu ,  William Dall'Acqua

发明人： Genevieve Losonsky ,  Edward M. Connor ,  James F. Young ,  Herren Wu ,  William Dall'Acqua

IPC分类号： A61K39/42

CPC分类号： C07K16/1027 ,  A61K2039/505 ,  A61K2039/543 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/72 ,  C07K2317/92 ,  C07K2317/94

摘要： The present invention provides methods for preventing, managing, treating and/or ameliorating a Respiratory Syncytial Virus (RSV) infection (e.g., acute RSV disease, or a RSV upper respiratory tract infection (URI) and/or lower respiratory tract infection (LRI)), otitis media (preferably, stemming from, caused by or associated with a RSV infection, such as a RSV URI and/or LRI), and/or a symptom or respiratory condition relating thereto (e.g., asthma, wheezing, and/or reactive airway disease (RAD)) in a subject, comprising administering to said human an effective amount of one or more antibodies that immunospecifically bind to one or more RSV antigens with a high affinity and/or high avidity. In some embodiments, one or more antibodies comprise a modified IgG constant domain, or FcRn-binding fragment thereof resulting in longer in vivo serum half-life. In particular embodiments the methods of the invention comprising administering to subject an effective amount of one or more modified antibodies that immunospecifically bind to one or more RSV antigens with an association rate (kon) of at least 2×105 M−1s−1 and a dissociation rate (koff) of less than 5×10−4 s−1.

摘要翻译： 本发明提供了用于预防，治疗和/或改善呼吸道合胞病毒（RSV）感染（例如急性RSV疾病或RSV上呼吸道感染（URI））和/或下呼吸道感染（LRI）的方法， ），中耳炎（优选来源于，由RSV感染引起或与RSV感染相关联，例如RSV URI和/或LRI），和/或与其相关的症状或呼吸病症（例如，哮喘，喘息和/或 反应性气道疾病（RAD）），包括向所述人施用有效量的一种或多种以高亲和力和/或高亲合力免疫特异性结合一种或多种RSV抗原的抗体。 在一些实施方案中，一种或多种抗体包含修饰的IgG恒定结构域或其FcRn结合片段，导致更长的体内血清半衰期。 在具体实施方案中，本发明的方法包括施用有效量的一种或多种经一免疫特异性结合一种或多种RSV抗原的修饰的抗体，其具有至少2×10 5 M-1s-1的缔合速率（kon）和 解离速率（koff）小于5×10-4 s-1。